Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02045719

Acronym

cat´sclaw

Enrollment

Registered

2014-01-27

Start date

2013-12-31

Completion date

2014-09-30

Last updated

2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Keywords

cat´s claw, uncaria tomentosa, quality of life, no further therapeutic options

Brief summary

Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and antitumor properties. Patients and methods: This prospective phase II study will assess the effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals with advanced solid tumors, with no further therapeutic options and with at least 2 months life expectancy. In addition, several biochemical and inflammatory parameters will be analyzed.

Interventions

DRUGuncaria tomentosa (cat´s claw)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* individuals with advanced solid tumors, with no further therapeutic options and with at least 2 moths life expectancy * individuals 18 years of age and older * creatinine levels up to twice the upper limit of normal (ULN) * alanine (ALT) and aspartate (ASP) transaminase levels up to twice the ULN and direct bilirubin (DB) levels up to 1.5 times the ULN * in cases with pre-existing liver disease, the ALT, ASP and DB levels could be up to 2.5 times the ULN

Exclusion criteria

* pregnant and breastfeeding women * individuals using chemotherapy or other tumor-targeting antineoplastic treatments, except for antalgic radiotherapy * severe kidney or liver failure * known hypersensitiveness to the components of the medication used * past history of emotional disorders that could interfere with the data collection.

Design outcomes

Primary

Measure	Time frame	Description
assessment of benefits on quality of life after treatment during two months	two months	Assess the efficacy and safety of a dry extract of U. tomentosa on individuals who had solid tumors with no further therapeutic options

Countries

Brazil

Contacts

Primary ContactLarissa de Paula

lariclpaula@hotmail.com5511992951626

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026